Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientif...(Oct. 18 2009) -- Safety Profiles of D...),Health

Date:10/16/2009

Oct. 18, 2009) -- Safety Profiles of Disease-Modifying Anti-Rheumatic Drugs and Biologics in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry Lead author: Gibofsky, A. Abstract No. 1593 (Sunday, Oct. 18, 2009) -- Identifying Clinical Features of Disseminated Histoplasmosis in Patients Receiving TNF Inhibitors Lead author: McCroskery, P. Abstract No. 999 (Monday, Oct. 19, 2009)

Gary L. Stiles, M.D., executive vice president, Pfizer, added, "Amgen and Pfizer are committed to ongoing research of ENBREL to grow the overall amount of information available about ENBREL and its safety and efficacy profile."

ABOUT RHEUMATOID ARTHRITIS

According to the Arthritis Foundation, approximately 1.3 million Americans are affected by rheumatoid arthritis (RA), which can cause pain, stiffness, swelling and limitation in the motion and function of multiple joints. If RA is left untreated, joint damage caused by the disease can impair function, disabling some patients.

ABOUT ENBREL

ENBREL is a soluble form of a fully human tumor necrosis factor (TNF) receptor and has 17 years of collective clinical experience with an established safety profile. ENBREL was first approved in 1998 for moderate to severe rheumatoid arthritis and was later approved to treat children and adolescents with juvenile rheumatoid arthritis (now called juvenile idiopathic arthritis) in 1999. ENBREL was approved in 2004 to treat moderate to severe plaque psoriasis in adults.

ENBREL indications in the U.S.:

• ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
• ENBREL is indicated for reducing the signs and symptoms of moderately to severely activ
  '/>"/>

SOURCE Amgen Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
2. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Tuesday, October 27
3. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Monday, October 26
4. Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25
5. Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24
6. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
7. PolyOne Presented with Frost & Sullivan Medical Product Award
8. CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
9. Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
10. Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the Tipping Point in Treating Pressure Ulcers
11. CRF announces late breaking trials to be presented at TCT 2009 in San Francisco